Recombinant Human CLTCL1 protein

CLathrin Heavy Chain Like 1 (CLTCL1), also known as CLTC or CLathrin Heavy Chain 2. is a key component of the clathrin protein family involved in intracellular membrane trafficking and vesicle formation. Clathrin plays a central role in receptor-mediated endocytosis, organelle biogenesis, and synaptic vesicle recycling by forming polyhedral lattices that coat membranes during vesicle budding. CLTCL1 shares structural homology with the canonical clathrin heavy chain (CLTC) but exhibits distinct tissue-specific expression patterns and functional roles. While CLTC is ubiquitously expressed, CLTCL1 is predominantly found in neuronal tissues, endocrine cells, and certain cancers, suggesting specialized regulatory functions in these contexts.

Recombinant CLTCL1 protein is engineered through molecular cloning techniques to enable controlled in vitro studies. Typically produced in prokaryotic (e.g., E. coli) or eukaryotic (e.g., mammalian or insect cell) expression systems, the recombinant protein retains functional domains critical for triskelion assembly, adaptor protein binding, and membrane curvature induction. Its production often includes purification tags (e.g., His-tag) for isolation and biochemical characterization. Researchers utilize recombinant CLTCL1 to investigate its unique interactions with accessory proteins like AP-1/2 complexes, dynamin, and huntingtin-associated proteins, which are essential for understanding its role in neurological disorders, endocrine secretion, and cancer metastasis. Dysregulation of CLTCL1 has been linked to neurodevelopmental defects, tumor progression, and impaired glucose metabolism, making it a potential therapeutic target. Current studies focus on its isoform-specific mechanisms, post-translational modifications, and crosstalk with other trafficking pathways. The availability of recombinant CLTCL1 accelerates structural analysis, drug screening, and functional assays to decipher its pathophysiological significance.